Volume 68, Issue 4, Pages (October 2015)

Slides:

Advertisements

Similar presentations

Volume 70, Issue 2, Pages (August 2016)

Advertisements

Volume 68, Issue 4, Pages (October 2015)

Volume 63, Issue 3, Pages (March 2013)

Pascal Rischmann European Urology Supplements

Volume 71, Issue 6, Pages (June 2017)

Volume 64, Issue 3, Pages (September 2013)

Volume 58, Issue 2, Pages (August 2010)

Pulmonary Hypertension Is Associated with Mortality and Cardiovascular Events in Chronic Kidney Disease Patients Am J Nephrol 2017;45: DOI: /

Volume 69, Issue 5, Pages (May 2016)

Volume 57, Issue 1, Pages (January 2010)

Volume 59, Issue 3, Pages (March 2011)

Contemporary Management of the Painful Bladder: A Systematic Review

Maintenance Bacillus Calmette-Guérin: The Standard of Care for the Prophylaxis and Management of Intermediate- and High-Risk Non–Muscle-Invasive Bladder.

Volume 56, Issue 3, Pages (September 2009)

Volume 73, Issue 2, Pages (February 2018)

Volume 49, Issue 2, Pages (February 2006)

Volume 68, Issue 3, Pages (September 2015)

Volume 69, Issue 1, Pages (January 2016)

Volume 69, Issue 5, Pages (May 2016)

Volume 69, Issue 1, Pages (January 2016)

Volume 51, Issue 3, Pages (March 2007)

Volume 69, Issue 2, Pages (February 2016)

Volume 66, Issue 6, Pages (December 2014)

Volume 71, Issue 6, Pages e171-e172 (June 2017)

Ashish M. Kamat, Sima Porten European Urology

Volume 73, Issue 5, Pages (May 2018)

Volume 72, Issue 5, Pages (November 2017)

Volume 51, Issue 5, Pages (May 2007)

Volume 52, Issue 4, Pages (October 2007)

Volume 63, Issue 4, Pages (April 2013)

Volume 63, Issue 1, Pages (January 2013)

What is New in Bladder Cancer Diagnosis and Management?

Clinical Practice Recommendations for the Management of Non–Muscle Invasive Bladder Cancer Donald Lamm, Marc Colombel, Raj Persad, Mark Soloway, Andreas.

The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.

Volume 55, Issue 6, Pages (June 2009)

Volume 54, Issue 4, Pages (October 2008)

Volume 66, Issue 4, Pages (October 2014)

Volume 60, Issue 4, Pages (October 2011)

Volume 61, Issue 4, Pages (April 2012)

Volume 70, Issue 4, Pages (October 2016)

Volume 70, Issue 4, Pages (October 2016)

Volume 70, Issue 5, Pages (November 2016)

Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma Viktor Grünwald, Xun Lin, Daniel Kalanovic,

Volume 57, Issue 4, Pages e41-e42 (April 2010)

Clinical Practice Recommendations for the Management of Non–Muscle Invasive Bladder Cancer Donald Lamm, Marc Colombel, Raj Persad, Mark Soloway, Andreas.

Volume 71, Issue 6, Pages (June 2017)

Volume 64, Issue 4, Pages (October 2013)

Volume 66, Issue 6, Pages (December 2014)

Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward? Michel Bolla European.

Performance of the Bladder EpiCheck™ Methylation Test for Patients Under Surveillance for Non–muscle-invasive Bladder Cancer: Results of a Multicenter,

Long-term Cancer-specific Survival in Patients with High-risk, Non–muscle-invasive Bladder Cancer and Tumour Progression: A Systematic Review Sven van.

Volume 70, Issue 2, Pages (August 2016)

Volume 53, Issue 1, Pages (January 2008)

Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic.

Volume 50, Issue 3, Pages (September 2006)

Selma Masic, Janet E. Cowan, Samuel L. Washington, Hao G

Anna Grenabo Bergdahl, Erik Holmberg, Sue Moss, Jonas Hugosson

Current Approaches to the Management of Non-Muscle Invasive Bladder Cancer: Comparison of Current Guidelines and Recommendations Raj Persad, Donald Lamm,

The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.

Volume 59, Issue 4, Pages (April 2011)

Bladder Cancer: Highlights from 2006

European Urology is “Your” Journal

Volume 68, Issue 5, Pages (November 2015)

Gender differences in treatment outcomes of tuberculosis patients in Taiwan: a prospective observational study J.-Y. Feng, S.-F. Huang, W.-Y. Ting, Y.-C.

Volume 52, Issue 4, Pages (October 2007)

Prognostic Factors in Non–Muscle-Invasive Bladder Tumors

Early Single-Instillation Chemotherapy Has No Real Benefit and Should Be Abandoned in Non–Muscle-Invasive Bladder Cancer Sten Holmäng European Urology.

Volume 52, Issue 1, Pages (July 2007)

Volume 54, Issue 1, Pages (July 2008)

Maximilian Burger, Ashish M. Kamat, David McConkey

Presentation transcript:

Volume 68, Issue 4, Pages 611-617 (October 2015) Long-term Outcome of Patients with Frequently Recurrent Non–muscle-invasive Bladder Carcinoma Treated with One Perioperative Plus Four Weekly Instillations of Mitomycin C Followed by Monthly Bacillus Calmette-Guérin (BCG) or Alternating BCG and Interferon-α2b Instillations: Prospective Randomised FinnBladder-4 Study Riikka Järvinen, Timo Marttila, Eero Kaasinen, Erkki Rintala, Sirpa Aaltomaa, Jukka Kallio, Tapani Liukkonen, Veli-Matti Puolakka, Marjo Seppänen, Kari Tuhkanen, Markku Vaarala, Jouko Viitanen, Peter J. Boström European Urology Volume 68, Issue 4, Pages 611-617 (October 2015) DOI: 10.1016/j.eururo.2015.02.022 Copyright © 2015 European Association of Urology Terms and Conditions

Fig. 1 The cumulative incidence curves of time to first recurrence in the mitomycin C (MMC) and bacillus Calmette-Guérin (BCG) group and in the MMC and BCG/interferon-α2b group. BCG=bacillus Calmette-Guérin; CI=confidence interval; HR=hazard ratio; IFN=interferon-α2b; MMC=mitomycin C. European Urology 2015 68, 611-617DOI: (10.1016/j.eururo.2015.02.022) Copyright © 2015 European Association of Urology Terms and Conditions

Fig. 2 The cumulative incidence curves of time to progression in the mitomycin C (MMC) and bacillus Calmette-Guérin (BCG) group and in the MMC and BCG/interferon-α2b group. BCG=bacillus Calmette-Guérin; CI=confidence interval; HR=hazard ratio; IFN=interferon-α2b; MMC=mitomycin C. European Urology 2015 68, 611-617DOI: (10.1016/j.eururo.2015.02.022) Copyright © 2015 European Association of Urology Terms and Conditions

Fig. 3 The cumulative incidence curves of disease-specific mortality and the Kaplan-Meier curves of overall survival in the mitomycin C (MMC) and bacillus Calmette-Guérin (BCG) group and in the MMC and BCG/interferon-α2b group. BCG=bacillus Calmette-Guérin; CI=confidence interval; HR=hazard ratio; IFN=interferon-α2b; MMC=mitomycin C. European Urology 2015 68, 611-617DOI: (10.1016/j.eururo.2015.02.022) Copyright © 2015 European Association of Urology Terms and Conditions